Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Completion of Unwinding its Acquisition of Blu Dot Systems Inc. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Janux Therapeutics Inc JANX

Healthcare Biotechnology
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is... see more

Current News (NDAQ:JANX)

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Business Wire February 26, 2026

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

Business Wire February 17, 2026

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

Business Wire January 26, 2026

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

Business Wire January 22, 2026

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

Business Wire December 23, 2025

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Business Wire December 1, 2025

Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC

Business Wire November 24, 2025

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Business Wire November 6, 2025

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Business Wire August 7, 2025
View More News ››

Opinion & Analysis (NDAQ:JANX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:JANX)

$JANX Climbs, $MYNZ Gains Momentum

$JANX surges 48.8% to $59.86 on investor confidence in its cancer immunotherapy advancements. Similarly, $MYNZ’s rebound post-split...
IronFocus77 - December 4, 2024

Janux Therapeutics, Inc. (NASDAQ:JANX): A Promising Biopharm

http://beyondspx.com/2024/07/31/janux-therapeutics-inc-nasdaqjanx-a-promising-biopharmaceutical-company-developing-innovative-tumor...
MikeTester - August 2, 2024
View more Bullboard ››

Coelacanth Energy Inc.

Coelacanth Energy Inc.

Coelacanth Energy Inc., an oil and natural gas company, engages in the acquisition, development, exploration, and production ...
View More »

Podcasts